What is immunosuppression induction therapy?

What is immunosuppression induction therapy?

Induction immunosuppression is relatively intense prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. It is typically of such potency that its prolonged use is prohibitively toxic.

What is Thymoglobulin induction therapy?

Background: Induction therapy is used to reduce the incidence of graft rejection and delayed graft function. Thymoglobulin is the most used inductor agent in deceased donor kidney transplantation due to its lower rejection and delayed graft function rates.

What does induction mean in transplant?

The immunosuppressive regimen after kidney transplantation typically includes initial induction with an antilymphocyte biological agent, usually either a T lymphocyte–depleting agent or an IL‐2 receptor antagonist (IL2RA). The primary aim of induction therapy is to reduce the risk of acute rejection.

What are the three types of immunosuppressive drugs used to prevent organ rejection?

Tacrolimus (Prograf) Cyclosporine (Neoral) Mycophenolate Mofetil (CellCept)

Which immunosuppressive therapies are used for induction therapy at the time of transplantation and immediately post transplantation?

Antibody Therapy Induction involves the use of high-intensity immunosuppression immediately after transplant, when the risk of rejection is highest.

Which of the following medications are commonly used as induction immunosuppressive therapy?

All of the induction immunosuppressive agents currently used are biological agents and are either monoclonal (muromonab-CD3, daclizumab, basiliximab, alemtuzumab) or polyclonal (antithymocyte globulin [equine] or antithymocyte globulin [rabbit]) antibodies.

What is Thymoglobulin used for?

Background. Thymoglobulin (Thymoglobulin®; Genzyme, Cambridge, Mass., USA) is a purified polyclonal immunoglobulin used for prevention and treatment of acute rejection (AR) following renal transplantation. Thymoglobulin is mostly used for treating vascular, steroid-resistant and antibody-mediated rejection.

Is ATG the same as Thymoglobulin?

Uses. Two antithymocyte globulin (ATG) agents licensed for clinical use in the United States are Thymoglobulin (rabbit ATG, rATG, Genzyme) and Atgam (equine ATG, eATG, Pfizer).

What are the drugs used for induction in transplant surgery?

Is Thymoglobulin an immunoglobulin?

Thymoglobulin (Thymoglobulin®; Genzyme, Cambridge, Mass., USA) is a purified polyclonal immunoglobulin used for prevention and treatment of acute rejection (AR) following renal transplantation.

What is the significant of Thymoglobulin in renal transplantation?

Randomized studies have established the anti-rejection efficacy of Thymoglobulin in kidney transplantation. Experimental and clinical data suggest that Thymoglobulin administration may ameliorate ischemia reperfusion injury, thus reducing the incidence of delayed graft function (DGF).

How long does ATG treatment last?

If it works, ATG usually stops the need for blood transfusions within 3 months. Full success can take at least 9 months. Some patients may respond initially, but may later relapse and need another treatment.

How is thymoglobulin administered?

THYMOGLOBULIN is intended for intravenous use only. The recommended dosage of THYMOGLOBULIN for prophylaxis of acute rejection in patients receiving a kidney transplant is 1.5 mg/kg of body weight administered daily with the first dose initiated prior to reperfusion of the donor kidney.

Why is Thymoglobulin called rabbit?

Thymoglobulin is made by taking donated human white blood cells (T-lymphocytes) and injecting them into a rabbit. The rabbit’s blood makes its own antibodies (a blood protein) against these T-lymphocytes. These antibodies are then taken from the rabbit’s blood and made into Thymoglobulin.

What is thymoglobulin used for?

Is ATG the same as thymoglobulin?

What is the success rate of ATG treatment?

Immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine is the standard treatment for patients with severe aplastic anemia who do not have a human leukocyte antigen-matched related donor; it leads to a response rate of 60 to 70%.